Rahul Gosain, MD, of the Oncology Brothers, talks with Mafalda Oliveira, MD, PhD, about the emerging class of drugs — including oral SERDs and PROTAC estrogen receptor degraders — and whether they are working better for patients.
Estimated Read Time:
1 minute
SABCS Snippets: Next Generation Endocrine Therapy
Share
Recent Posts
-
December 15, 2025
-
December 15, 2025
-
FDA session offers closer look at approval process for HR-positive metastatic breast cancer therapies
December 15, 2025 -
December 15, 2025
